Jun Hyung Lee

Jun Hyung Lee

Auto-generated profile, based on publicly available information

Jun Hyung Lee

Wellmarkerbio Co., Ltd., Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
JKJoseph Kim
Joseph Kim
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
SHSeung-Woo Hong
Seung-Woo Hong
DJDong-Hoon Jin
Dong-Hoon Jin
Recepteur d’origine nantais (RON, MST1R) is a single-span transmembrane receptor tyrosine kinase (RTK) aberrantly expressed in numerous cancers, including various solid tumors. How naturally occurring splicing isoforms of RON, especially those which are constitutively activated, affect tumorigenesis and therapeutic response, is largely unknown. Here, we identified that presence of activated RON could be a possible factor for the development of resistance against anti-EGFR (cetuximab) therapy in colorectal cancer patient tissues. Also, we elucidated the roles of three splicing variants of RON, RON Δ155, Δ160, and Δ165 as tumor drivers in cancer cell lines. Subsequently, we designed an inhibitor of RON, WM-S1-030, to suppress phosphorylation thereby inhibiting the activation of the three RON variants as well as the wild type. Specifically, WM-S1-030 treatment led to potent regression of tumor growth in solid tumors expressing the RON variants Δ155, Δ160, and Δ165. Two mechanisms for the RON oncogenic activity depending on KRAS genotype was evaluated in our study which include activation of EGFR and Src, in a trimeric complex, and stabilization of the beta-catenin. In terms of the immunotherapy, WM-S1-030 elicited notable antitumor immunity in anti-PD-1 resistant cell derived mouse model, likely via repression of M1/M2 polarization of macrophages. These findings suggest that WM-S1-030 could be developed as a new treatment option for cancer patients expressing these three RON variants.

30 January 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
The development of first-generation immune-checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 ushered in a new era in anticancer therapy. Although immune-checkpoint blockade therapies have shown clinical success, a substantial number of patients yet fail to benefit. Many studies are under way to discover next-generation immunotherapeutic targets. Immunoglobulin superfamily member 1 (IGSF1) is a membrane glycoprotein proposed to regulate thyroid function. Despite containing 12 immunoglobin domains, a possible role for IGSF1, in immune response, remains unknown. Here, our studies revealed that IGSF1 is predominantly expressed in tumors but not normal tissues, and increased expression is observed in PD-L1low non–small cell lung cancer (NSCLC) cells as compared with PD-L1high cells. Subsequently, we developed and characterized an IGSF1-specific human monoclonal antibody, WM-A1, that effectively promoted antitumor immunity and overcame the limitations of first-generation immune-checkpoint inhibitors, likely via a distinct mechanism of action. We further demonstrated high WM-A1 efficacy in humanized peripheral blood mononuclear cells (PBMC), and syngeneic mouse models, finding additive efficacy in combination with an anti–PD-1 (a well-characterized checkpoint inhibitor). These findings support IGSF1 as an immune target that might complement existing cancer immunotherapeutics.

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Target identification was conducted to identify the counter-partner of IGSF1.

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Target identification was conducted to identify the counter-partner of IGSF1.

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
IGSF1 targeting antibody is developed and characterized by various methods.

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
IGSF1 targeting antibody is developed and characterized by various methods